AER estimates
This article was originally published in The Tan Sheet
Executive Summary
FDA revises its estimate for annual mandatory adverse event reports related to dietary supplement products to 856 from 960, based on the 214 AERs it received between Jan. 1 and April 15, according to a Sept. 15 Federal Register notice. In a separate same-day notice, FDA announces it received no comments following an October 2007 notice about information collection provisions for nonprescription drug AERs. The agency's estimate for annual serious OTC AERs will remain at 12,500 from approximately 50 respondents
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.